<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580408</url>
  </required_header>
  <id_info>
    <org_study_id>NIVINIHO</org_study_id>
    <nct_id>NCT03580408</nct_id>
  </id_info>
  <brief_title>Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma</brief_title>
  <official_title>A Prospective Phase II Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients Aged 61 Years And Older, With Classical Hodgkin Lymphoma And Coexisting Medical Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2
      weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET
      and CT scan responses. :

        -  In case of CMR according to Lugano Classification (Cheson et al.2014, PET-CT based
           response), patients will receive 18 additional cycles of Nivolumab, according to
           CT-based response at Cycle 12.

        -  In case of Partial Metabolic Response (PMR) or No Metabolic Response(NMR), according to
           Lugano Classification (Cheson et al.2014, PET-CT based response) patients will receive
           12 to 18 cycles of Nivolumab combined with Vinblastin according to CT-based response at
           Cycle 12.

        -  In case of progressive disease, according to Lugano Classification (Cheson et al.2014,
           PET-CT scan based response) patients will be considered in treatment failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Metabolic Response (CMR) rate (Deauville scale 1-3) at the end of treatment</measure>
    <time_frame>12 months</time_frame>
    <description>by the Lugano classification 2014</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of drug taken</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Event</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Metabolic Response (CMR) rate</measure>
    <time_frame>3 months</time_frame>
    <description>by the Lugano classification 2014 at the end of induction treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Coexisting Medical Conditions</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)
Consolidation treatment:
It depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :
For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.
Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)
In case of progressive disease , patients will be considered in treatment failure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>240 mg</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastin</intervention_name>
    <description>6mg/m²</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first diagnosis of classical Hodgkin lymphoma according to World Health Organization
             (WHO) criteria excluding nodular lymphocyte predominant subtype

          -  Age 61 years or older

          -  Unfit for poly chemotherapy because of co-morbidities evaluated by a Cumulative
             Illness Rating Scale (CIRS) score ≥6)

          -  No previous treatment for Hodgkin lymphoma

          -  Ann Arbor stages: I-IV

          -  Baseline 18-fluoro-2-deoxy-D-glucose (18F-FDG) PET-CT (PET0) performed before any
             treatment with at least one hypermetabolic lesion

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-3

          -  minimum life expectancy of 3 months

          -  covered by a social security system

          -  Men who are sexually active with women with childbearing potential must agree to
             follow instructions for method(s) of contraception for the duration of treatment with
             study drug and for at least 7 months after the last drug administration.

        Exclusion Criteria:

          -  Contra-indication to Nivolumab and /or Vinblastin

          -  Subjects with active interstitial pneumonitis

          -  Subjects with active infectious disease

          -  Subjects with active, known or suspected autoimmune disease. Are permitted to enroll:
             subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to
             autoimmune condition only requiring hormone replacement, psoriasis not requiring
             systemic treatment, or conditions not expected to recur in the absence of an external
             trigger.

          -  Any serious active disease, severe cardio-pulmonary, or metabolic disease interfering
             with normal application of protocol treatment (according to the investigator's
             decision)

          -  Any of the following abnormal laboratory values (unless due to underlying HL) :

               1. Calculated creatinine clearance &lt; 30 mL/min (MDRD formula)

               2. aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 2.5 times the upper
                  limit of normal (ULN)

               3. Serum total bilirubin &gt; 30µmol/L

               4. Neutrophils&lt;1 G/L or Platelets&lt;50 G/L, (unless related to bone infiltration by
                  lymphoma)

          -  Any history of cancer evolution requiring therapy during the last 3 years with the
             exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
             Patients previously diagnosed with prostate cancer are eligible if :

               1. Their disease was T1-T2a, N0, M0, with a Gleason score ≤ 7, and a prostate
                  specific antigen (PSA) ≤ 10 ng/mL prior to initial therapy,

               2. They had definitive curative therapy (ie, prostatectomy or radiotherapy) ≥ 2
                  years before Day 1 of Cycle 1,

               3. At a minimum 2 years following therapy they had no clinical evidence of prostate
                  cancer, and their PSA was undetectable if they underwent prostatectomy or &lt;1
                  ng/mL if they did not undergo prostatectomy.

          -  Uncontrolled diabetes mellitus leading to impossibility to perform PET scan

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study

          -  Adult person under legal protection

          -  Adult person unable to provide informed consent because of intellectual impairment,
             any serious medical condition, laboratory abnormality or psychiatric illness

          -  Subjects with know Human Immunodeficiency Virus (HIV) positivity

          -  Subjects with known active hepatitis B (HB) infection (positive Ag HB s or positive
             DNA polymerase chain reaction (PCR) or positive antibody anti-HB c with lack of
             antibody against HBs) or active hepatitis C infection (patients with positive HCV
             serology are eligible only if PCR is negative for known hepatitis C virus (HCV RNA)

          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;
             10mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration except for adrenal replacement steroid doses &gt; 10 mg
             daily prednisone equivalent in the absence of active autoimmune disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent RIBRAG</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Gustave Roussy Cancer, Villejuif, France - LYSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien LAZAROVICI</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Gustave Roussy Cancer, Villejuif, France - LYSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc ANDRE</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Dinant Godinne, UCL Namur, Yvoir - Belgium - LYSA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chloé GOURC BERTHOD</last_name>
    <phone>+334 72 66 93 33</phone>
    <email>chloe.gourc-berthod@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ka Lung WU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Az Sint Jan</name>
      <address>
        <city>Bruges</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia SNAUWAERT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire Saint LUC</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole STRAETMANS, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie MAEREVOET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Jolimont</name>
      <address>
        <city>Haine saint paul</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine NGIRABACU, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Az Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liesbeth SCHAUVLIEGE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Liege</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe BONNET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dinant Godinne</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc ANDRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc ANDRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline DELETTE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon - Hôpital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borhane Slama, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne BANOS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrien CHAUCHET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna SCHMITT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Claire GAC-BESNARD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Métropole Savoie</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian-Matteo PICA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Cacheux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien de Corbeil</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bertrand JOLY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP-Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien LE BRAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Hôpital le Bocage</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lysiane MOLINA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD de Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Morineau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel FLECK, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamel LARIBI, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Pascal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de LILLE - Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSHHAUSER, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed TOUATI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex 8</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle NICOLAS-VIRELIZIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Réda BOUABDALLAH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Metz-Thionville</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CARASSOU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe QUITTET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GASTINNE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Caremeau</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agathe RASCALOU-WAULTIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Brice, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Delarue, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital de la Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Gabarre, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Magendie - Hôpital du Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal BOUABDALLAH, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé GHESQUIERES, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers - Hôpital de La Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie GUIDEZ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Rene Dubos</name>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo GONZALEZ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy-Genevois - Site d'Annecy</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne PARRY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Durot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry LAMY-DE-LA-CHAPELLE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Roubaix</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abir FAWAZ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Saint Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent LAUNAY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc-Matthieu Fornecker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile BOREL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian ERTAULT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauriane CLEMENT FILIATRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>VILLEJUIF Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien LAZAROVICI, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Anti-PD1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

